Michael T. Schweizer
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Articles (12)
Unsupervised model predictions and patient/validation cohort sequencing metrics Sheet 1: DFCI Cohort I: Tumor phenotype by histology and estimates of tumor fraction, subtyping score, and inferred subtype calls using ctdPheno. Sheet 2: DFCI cohort I: Tumor phenotype by histology and estimates of tumor fraction, subtyping score, and inferred phenotypic subtype calls using different ATAC-seq site restricted analysis using ctdPheno. Sheet 3: DFCI cohort I: Tumor phenotype by histology and estimates of tumor fraction, subtyping score, and inferred phenotypic subtype calls using different ATAC-seq site restricted analysis using Keraon. Sheet 4: DFCI Cohort II: Tumor phenotype by histology, summary of clinical correlatives and estimates of tumor fraction, subtyping score, and inferred subtype calls using ctdPheno. Sheet 5: Histology, tumor fraction, subtype score, NEPC fraction, and subtype calls for WGS and ULP patient samples (UW cohort). Sheet 6: Complete sequencing metrics for DFCI cohort I. Sheet 7: Complete sequencing metrics for DFCI cohort II (ULP). Sheet 8: Complete sequencing metrics for DFCI cohort II (deep WGS) Sheet 9: Complete sequencing metrics and ichorCNA estimated tumor fractions for the UW cohort (ULP). Sheet 10: Complete sequencing metrics for the UW cohort (deep WGS) Sheet 11: Complete sequencing metrics for the healthy donor cohort. Sheet 12: Clinical data summary for UW cohort.
Year:
2025
Feature-region combination AUCs and benchmarking Sheet 1: Log2 fold-change, p-value, and q-value between ARPC and NEPC lines for central mean coverage in all queried (338) TFs (two tailed Mann-Whitney U test, Benjamini-Hochberg adjusted). Sheet 2: 100-fold cross-validation AUCs for all region and feature combinations subset by the ‘AR10’ overlapping features (see Methods). Sheet 3: 100-fold cross-validation AUCs for all region and feature combinations subset by the ‘Phenotype 47-defining’ overlapping features. Sheet 4: 100-fold cross-validation AUCs for all region and feature combinations (global). Sheet 5: Predictions scores, tumor fraction, depth of coverage, and subtype for benchmarking admixtures. Sheet 6: AUCs for unsupervised prediction of admixture subtypes grouped by tumor fraction and depth. Sheet 7: NEPC:ARPC ratio, tumor fraction, and ARPC and NEPC fraction predictions for mixed phenotype admixtures using Keraon (see Methods).
Year:
2025
PTM peak data and phenotype 47 fragment variability Sheet 1: PDX sample representation in 3 histone PTM CUT&RUN nucleosome profiling assays (H3K4me1, H2K27ac and H3K27me3). Sheet 2: Log2 fold-change, p-value, and q-value between ARPC and NEPC lines for coefficient of variation in the 47 phenotype defining gene bodies (two tailed Mann-Whitney U test, Benjamini-Hochberg adjusted). Sheet 3: Log2 fold-change, p-value, and q-value between ARPC and NEPC lines for coefficient of variation in the 47 phenotype defining gene promoters (two tailed Mann-Whitney U test, Benjamini-Hochberg adjusted).
Year:
2025
Differential regulation metrics and values for select features Sheet 1: Log2 fold-change, p-value, and q-value between ARPC and NEPC lines for NPS in the 47 phenotype defining gene bodies (two tailed Mann-Whitney U test, Benjamini-Hochberg adjusted). Sheet 2: Differentially expressed list of 514 transcription factor (TF). All statistical comparison and fold change estimation was done against ARPCs. Sheet 3: Log2 fold-change, p-value, and q-value between ARPC and NEPC lines for central mean coverage in 108 TFs overlapping RNA-Seq up/down regulated TFs (two tailed Mann-Whitney U test, Benjamini-Hochberg adjusted). Sheet 4: Paralogous transcription factors (TFs) for each of the 38 TFs with differential RNA expression between ARPC and NEPC and differential TFBS accessibility. Paralogous TFs that are also differentially expressed by RNAseq analysis of PDX tumors are shown in red text. Paralogs were obtained from ensembl biomart human genes GRCh38.p13 (http://uswest.ensembl.org/biomart/martview/64d8bd7fe9851a2501aece9b74b03631) Sheet 5: Mean values in ARPC, NEPC, and HD lines for central and window means for ARPC and NEPC specific open chromatin regions.
Year:
2025
A and B, Representative micrographs of HER2 IHC staining in prostate cancer ( A ) and urothelial cancer ( B ) autopsy specimens. C, Number of patients with at least one tumor with the indicated HER2 IHC score, color coded by cancer type. D, Number of tumors across all patients with the indicated HER2 IHC score, color coded by cancer type. E and F, Percent of tumors expressing the indicated level of HER2 staining by IHC according to the tumor site sampled in prostate ( E ) and urothelial ( F ) cancer cohorts. Anatomic sites with only one representative tumor were excluded. PC, prostate cancer; UC, urothelial carcinoma.
Year:
2025
A and B, Box plots indicating the relationship between HER2 score with protein expression of key cell surface antigens as measured by IHC in ( A ) prostate cancer and ( B ) urothelial cancer.
Year:
2025
HER2 is an oncogenic driver in multiple cancers and a predictive biomarker for HER2-targeted therapies. Although HER2-directed therapies like fam-trastuzumab deruxtecan are approved for HER2-positive breast and other solid tumors, the landscape of HER2 expression in advanced prostate cancer and urothelial carcinoma remains inadequately characterized. We evaluated HER2 protein expression in metastatic prostate cancer and urothelial carcinoma using a validated IHC assay on tissue microarrays constructed from the University of Washington Tissue Acquisition Necropsy Program. HER2 expression was scored using standardized gastric cancer criteria. Genomic analysis of ERBB2 alterations was conducted on a subset of samples. HER2 expression heterogeneity and its relationship with other surface markers were also evaluated. In the prostate cancer cohort ( n = 52 patients, 1–19 tumors per patient), HER2 expression was low, with no 3+ expression observed and only five (10%) patients exhibiting 2+ expression. Low-level ERBB2 copy-number gains were observed in some tumors but did not correlate with HER2 protein expression ( P = 0.2). In urothelial carcinoma ( n = 20, 2–6 tumors per patient), HER2 expression was more frequent, with ≥2+ expression observed in six (30%) cases and 3+ expression observed in three (15%) cases in at least one tumor. Urothelial carcinoma samples showed less heterogeneity, with more consistent expression across metastases. HER2 overexpression is rare and heterogeneous in metastatic prostate cancer, limiting its utility as a therapeutic target. HER2 expression is more prevalent and uniform in urothelial carcinoma. These findings underscore the importance of comprehensive HER2 assessment in advanced urothelial carcinoma and suggest that success of HER2-directed therapies in prostate cancer will require careful case selection. Significance: This study demonstrates that HER2 is rarely overexpressed in metastatic prostate cancer but is more common and consistent in urothelial carcinoma. These findings highlight the need for HER2 testing in urothelial cancer and suggest that HER2-targeted therapies in prostate cancer will require careful patient selection.
Year:
2025
A and B, Mosaic plots indicating the relationship between ERBB2 genomic status as assessed by unadjusted copy number and HER2 IHC in ( A ) prostate and ( B ) urothelial cancers. C and D, Box plots indicating the relationship between HER2 RNA expression with ( C ) prostate and ( D ) urothelial cancers. PC, prostate cancer; UC, urothelial carcinoma.
Year:
2025
PURPOSE While 177 Lu-PSMA-617 (LuPSMA) is an effective therapy for many patients with metastatic castration-resistant prostate cancer (mCRPC), biomarkers associated with outcomes are not well defined. We hypothesized that prostate cancer mutational profile may associate with clinical activity of LuPSMA. We devised a study to evaluate associations between mCRPC mutational profile with LuPSMA clinical outcomes. METHODS This was a multicenter retrospective analysis of patients with mCRPC with next-generation sequencing (NGS) who received LuPSMA. PSA 50 response (ie, ≥50% decline in prostate-specific antigen [PSA]) rate, PSA progression free survival (PSA PFS), and overall survival (OS) were compared between genetically defined subgroups. RESULTS One hundred twenty-six patients with NGS results who received at least one cycle of LuPSMA were identified. The median age was 73 (IQR, 68-78) years, 124 (98.4%) received ≥1 prior androgen receptor-signaling inhibitor, and 121 (96%) received ≥1 taxane-based chemotherapy regimen. Fifty-eight (46%) patients with a DNA damage repair gene mutation (DNA damage response group) and 59 (46.8%) with a mutation in TP53, RB1, or PTEN tumor suppressor genes (TSG group) were identified. After adjusting for relevant confounders, the presence of ≥1 TSG mutation was associated with shorter PSA PFS (hazard ratio [HR], 1.93 [95% CI, 1.05 to 3.54]; P = .034) and OS (HR, 2.65 [95% CI, 1.15 to 6.11]; P = .023). There was improved OS favoring the DNA damage response group (HR, 0.37 [95% CI, 0.14 to 0.97]; P = .044) on multivariable analysis. Univariate analysis of patients with ATM mutations had significantly higher rates of PSA 50 response, PSA PFS, and OS. CONCLUSION Outcomes on LuPSMA varied on the basis of mutational profile. Prospective studies to define the clinical activity of LuPSMA in predefined genomic subgroups are justified.
Year:
2024
Purpose: Cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitors radically changed the treatment paradigm for breast cancer. Similar to estrogen receptor in breast cancer, androgen receptor signaling activates cyclin D–CDK4/6, driving proliferation and resistance to hormonal manipulation in prostate cancer. This study was designed to detect signals of clinical activity for abemaciclib in treatment-refractory metastatic castration-resistant prostate cancer (mCRPC). Patients and Methods: Eligible patients had progressive mCRPC, measurable disease, and previously received ≥1 novel hormonal agent(s) and 2 lines of taxane chemotherapy. Abemaciclib 200 mg twice daily was administered on a continuous dosing schedule. Primary endpoint was objective response rate (ORR) without concurrent bone progression. This study was designed to detect a minimum ORR of 12.5%. Results: At trial entry, 40 (90.9%) of 44 patients had objective radiographic disease progression, 4 (9.1%) had prostate-specific antigen (PSA)–only progression, and 20 (46.5%) had visceral metastases (of these, 60% had liver metastases). Efficacy analyses are as follows: ORR without concurrent bone progression: 6.8%; disease control rate: 45.5%; median time to PSA progression: 6.5 months [95% confidence interval (CI), 3.2–NA]; median radiographic PFS; 2.7 months (95% CI, 1.9–3.7); and median OS, 8.4 months (95% CI, 5.6–12.7). Most frequent grade ≥3 treatment-emergent adverse events (AE) were neutropenia (25.0%), anemia, and fatigue (11.4% each). No grade 4 or 5 AEs were related to abemaciclib. Conclusions: Abemaciclib monotherapy was well tolerated and showed clinical activity in this heavily pretreated population, nearly half with visceral metastases. This study is considered preliminary proof-of-concept and designates CDK4/6 as a valid therapeutic target in prostate cancer.
Year:
2024
Year:
2024
Year:
2024
Collaborators (28)
Gwenaelle Gravis
Praticien Hospitalier Spécialiste Oncologie; Head of the onco-urology (since 2001) , Head of the outpatient unit (2002-2018) , Reviewer for the Clinical Research protocol (since 2017)
Institut Paoli-Calmettes
Hyun Jung Lee
Assistant Professor
Pusan National University Yangsan Hospital
Kami Ahmad
Principal Investigator
Fred Hutchinson Cancer Research Center
Andrew C. Hsieh
Fred Hutchinson Cancer Research Center
Michael Meers
Assistant Professor
Washington University in St. Louis
Lawrence True
Professor
University of Washington
Navonil De Sarkar
Assistant Professor (Tenure Track), Research Member Cancer Center
Medical College of Wisconsin
Gavin Ha
Associate Professor
Fred Hutchinson Cancer Research Center
Michael Haffner
Fred Hutchinson Cancer Research Center
Steven Henikoff
Fred Hutchinson Cancer Research Center
Stéphane Oudard
Université Paris-Saclay
SANDIPAN BRAHMA
Assistant Professor
University of Nebraska Medical Center
Sonali Arora
Fred Hutchinson Cancer Research Center
Heather H. Cheng
Professor
University of Washington
Petros Grivas
University of Washington
Radhika A Patel
Fred Hutch Cancer Center
Eva Corey
Professor
University of Washington
Evan Y. Yu
University of Washington
Colm Morrissey
Research Professor
University of Washington
Colin Pritchard
University of Washington
Atish Choudhury
Dana-Farber Cancer Institute
Bruce Montgomery
University of Washington
Peter S. Nelson
Fred Hutchinson Cancer Research Center
Derek Janssens
Assistant Professor
Van Andel Institute
Neeraj Agarwal
Faculty Member
Dana-Farber Cancer Institute
Maria Tretiakova
Professor
University of Washington
Jessica Hawley
Assistant Professor
University of Washington
Daniel Castellano
-
Make your next move.
Prepare your application
Review drafts before you send them.